logo
Jabil Posts Third Quarter Results

Jabil Posts Third Quarter Results

Yahoo15 hours ago

Raises Fiscal 2025 Outlook
ST. PETERSBURG, Fla., June 17, 2025--(BUSINESS WIRE)--Today, Jabil Inc. (NYSE: JBL), reported preliminary, unaudited financial results for its third quarter of fiscal year 2025.
Third Quarter of Fiscal Year 2025 Highlights:
Net revenue: $7.8 billion
U.S. GAAP operating income: $403 million
U.S. GAAP diluted earnings per share: $2.03
Core operating income (Non-GAAP): $420 million
Core diluted earnings per share (Non-GAAP): $2.55
"We delivered a strong third quarter, outperforming expectations across key end-markets such as cloud, data center infrastructure, and capital equipment," said CEO Mike Dastoor. "Our Intelligent Infrastructure segment remains a critical growth engine, benefiting from accelerating AI-driven demand. Despite softness in areas like EVs, Renewables, and 5G, our diversified portfolio and operational discipline have us tracking toward record core earnings per share. Looking ahead, we remain focused on enhancing core margins, optimizing cash flow, and returning value to shareholders—primarily through share repurchases and targeted investments in higher-margin opportunities," he added.
Fourth Quarter of Fiscal Year 2025 Outlook:
• Net revenue
$7.1 billion to $7.8 billion
• U.S. GAAP operating income
$331 million to $411 million
• U.S. GAAP diluted earnings per share
$1.79 to $2.37 per diluted share
• Core operating income (Non-GAAP)(1)
$428 million to $488 million
• Core diluted earnings per share (Non-GAAP)(1)
$2.64 to $3.04 per diluted share
____________________
(1)
Core operating income and core diluted earnings per share exclude anticipated adjustments of $17 million for amortization of intangibles (or $0.14 per diluted share) and $20 million for stock-based compensation expense and related charges (or $0.18 per diluted share) and $60 million to $40 million (or $0.53 to $0.35 per diluted share) for restructuring, severance and related charges.
Fiscal Year 2025 Outlook:
• Net revenue
$29 billion
• Core operating margin (Non-GAAP)
5.4%
• Core diluted earnings per share (Non-GAAP)
$9.33 per diluted share
• Adjusted free cash flow (Non-GAAP)
$1.2+ billion
(Definitions: "U.S. GAAP" means U.S. generally accepted accounting principles. Jabil defines core operating income as U.S. GAAP operating income less amortization of intangibles, stock-based compensation expense and related charges, restructuring, severance and related charges, distressed customer charges, loss on disposal of subsidiaries, settlement of receivables and related charges, impairment of notes receivable and related charges, goodwill impairment charges, business interruption and impairment charges, net, (gain) loss from the divestiture of businesses, acquisition and divestiture related charges, plus other components of net periodic benefit cost. Jabil defines core earnings as core operating income, less loss on debt extinguishment, loss (gain) on securities, other components of net periodic benefit cost, income (loss) from discontinued operations, gain (loss) on sale of discontinued operations and certain other expenses, net of tax and certain deferred tax valuation allowance charges. Jabil defines core diluted earnings per share as core earnings divided by the weighted average number of outstanding diluted shares as determined under U.S. GAAP. Jabil defines adjusted free cash flow as net cash provided by (used in) operating activities less net capital expenditures (acquisition of property, plant and equipment less proceeds and advances from sale of property, plant and equipment). Jabil reports core operating income, core earnings, core diluted earnings per share and adjusted free cash flow to provide investors an additional method for assessing operating income, earnings, diluted earnings per share and free cash flow from what it believes are its core manufacturing operations. See the accompanying reconciliation of Jabil's core operating income to its U.S. GAAP operating income, its calculation of core earnings and core diluted earnings per share to its U.S. GAAP net income and U.S. GAAP earnings per share and additional information in the supplemental information.)
Forward Looking Statements: This release contains forward-looking statements, including those regarding our anticipated financial results for our third quarter of fiscal year 2025 and our guidance for future financial performance in our fourth quarter of fiscal year 2025 (including, net revenue, U.S. GAAP operating income, U.S. GAAP diluted earnings per share, core operating income (Non-GAAP), core diluted earnings per share (Non-GAAP) results and the components thereof, including but not limited to amortization of intangibles, stock-based compensation expense and related charges and restructuring, severance and related charges); and our full year 2025 (including net revenue, core operating margin (Non-GAAP), core diluted earnings per share (Non-GAAP), the components thereof and adjusted free cash flow (Non-GAAP)). The statements in this release are based on current expectations, forecasts and assumptions involving risks and uncertainties that could cause actual outcomes and results to differ materially from our current expectations. Such factors include, but are not limited to: our determination as we finalize our financial results for our third quarter of fiscal year 2025 that our financial results and conditions differ from our current preliminary unaudited numbers set forth herein; scheduling production, managing growth and capital expenditures and maximizing the efficiency of our manufacturing capacity effectively; managing rapid declines or increases in customer demand and other related customer challenges that may occur; our dependence on a limited number of customers; our ability to purchase components efficiently and reliance on a limited number of suppliers for critical components; risks arising from relationships with emerging companies; changes in technology and competition in our industry; our ability to introduce new business models or programs requiring implementation of new competencies; competition; transportation issues; our ability to maintain our engineering, technological and manufacturing expertise; retaining key personnel; risks associated with international sales and operations, including geopolitical uncertainties; energy price increases or shortages; our ability to achieve expected profitability from acquisitions; risk arising from our restructuring activities; issues involving our information systems, including security issues; regulatory risks (including the expense of complying, or failing to comply, with applicable regulations; risk arising from design or manufacturing defects; risk arising from compliance, or failure to comply, with environmental, health and safety laws or regulations; risk arising from litigation; and intellectual property risk); financial risks (including customers or suppliers who become financially troubled; turmoil in financial markets; tax risks; credit rating risks; risks of exposure to debt; currency fluctuations; and asset impairment); changes in financial accounting standards or policies; risk of natural disaster, climate change or other global events; and risks arising from expectations relating to environmental, social and governance considerations. Additional factors that could cause such differences can be found in our Annual Report on Form 10-K for the fiscal year ended August 31, 2024 and our other filings with the Securities and Exchange Commission. We assume no obligation to update these forward-looking statements.
Supplemental Information Regarding Non-GAAP Financial Measures: Jabil provides supplemental, non-GAAP financial measures in this release to facilitate evaluation of Jabil's core operating performance. These non-GAAP measures exclude certain amounts that are included in the most directly comparable U.S. GAAP measures, do not have standard meanings and may vary from the non-GAAP financial measures used by other companies. Management believes these "core" financial measures are useful measures that facilitate evaluation of the past and future performance of Jabil's ongoing operations on a comparable basis.
Jabil reports core operating income, core earnings, core diluted earnings per share and adjusted free cash flows to provide investors an additional method for assessing operating income, earnings, earnings per share and free cash flow from what it believes are its core manufacturing operations. Among other uses, management uses non-GAAP financial measures to make operating decisions, assess business performance and as a factor in determining certain employee performance when determining incentive compensation.
The Company determines an annual normalized tax rate ("normalized core tax rate") for the computation of the non-GAAP (core) income tax provision to provide better consistency across reporting periods. In estimating the normalized core tax rate annually, the Company utilizes a full-year financial projection of core earnings that considers the mix of earnings across tax jurisdictions, existing tax positions, and other significant tax matters. The Company may adjust the normalized core tax rate during the year for material impacts from new tax legislation or material changes to the Company's operations.
Detailed definitions of certain of the core financial measures are included above under "Definitions" and a reconciliation of the disclosed core financial measures to the most directly comparable U.S. GAAP financial measures is included under the heading "Supplemental Data" at the end of this release.
Meeting and Replay Information: Jabil will hold a conference call today at 8:30 a.m. ET to discuss its earnings for the third quarter of fiscal year 2025. To access the live audio webcast and view the accompanying slide presentation, visit the Investor Relations section of Jabil's website, located at https://investors.jabil.com. An archived replay of the webcast will also be available after completion of the call.
About Jabil: At Jabil (NYSE: JBL), we are proud to be a trusted partner for the world's top brands, offering comprehensive engineering, supply chain, and manufacturing solutions. With over 50 years of experience across industries and a vast network of over 100 sites worldwide, Jabil combines global reach with local expertise to deliver both scalable and customized solutions. Our commitment extends beyond business success as we strive to build sustainable processes that minimize environmental impact and foster vibrant and diverse communities around the globe. Discover more at www.jabil.com.
JABIL INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions)
May 31, 2025(unaudited)
August 31, 2024
ASSETS
Current assets:
Cash and cash equivalents
$
1,523
$
2,201
Accounts receivable, net
4,004
3,533
Contract assets
1,107
1,071
Inventories, net
4,772
4,276
Prepaid expenses and other current assets
2,376
1,710
Total current assets
13,782
12,791
Property, plant and equipment, net
2,881
3,024
Operating lease right-of-use assets
431
360
Goodwill and intangible assets, net
1,119
804
Deferred income taxes
108
96
Other assets
266
276
Total assets
$
18,587
$
17,351
LIABILITIES AND EQUITY
Current liabilities:
Current installments of notes payable and long-term debt
$
499
$

Accounts payable
7,614
6,190
Accrued expenses
5,806
5,499
Current operating lease liabilities
96
93
Total current liabilities
14,015
11,782
Notes payable and long-term debt, less current installments
2,385
2,880
Other liabilities
338
416
Non-current operating lease liabilities
350
284
Income tax liabilities
97
109
Deferred income taxes
115
143
Total liabilities
17,300
15,614
Commitments and contingencies
Equity:
Jabil Inc. stockholders' equity:
Preferred stock


Common stock


Additional paid-in capital
2,998
2,841
Retained earnings
6,173
5,760
Accumulated other comprehensive loss
(10
)
(46
)
Treasury stock, at cost
(7,876
)
(6,818
)
Total Jabil Inc. stockholders' equity
1,285
1,737
Noncontrolling interests
2

Total equity
1,287
1,737
Total liabilities and equity
$
18,587
$
17,351
JABIL INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in millions, except for per share data)
(Unaudited)
Three months ended
Nine months ended
May 31, 2025
May 31, 2024
May 31, 2025
May 31, 2024
Net revenue
$
7,828
$
6,765
$
21,550
$
21,919
Cost of revenue
7,147
6,157
19,687
19,906
Gross profit
681
608
1,863
2,013
Operating expenses:
Selling, general and administrative
274
268
835
890
Research and development
7
9
22
29
Amortization of intangibles
17
12
45
27
Restructuring, severance and related charges
16
55
144
252
Gain from the divestiture of businesses
(45
)

(45
)
(944
)
Acquisition and divestiture related charges
9
3
17
64
Operating income
403
261
845
1,695
Loss on securities
46

46

Interest and other, net
67
60
186
197
Income before income tax
290
201
613
1,498
Income tax expense
68
72
174
248
Net income
222
129
439
1,250
Net income attributable to noncontrolling interests, net of tax




Net income attributable to Jabil Inc.
$
222
$
129
$
439
$
1,250
Earnings per share attributable to the stockholders of Jabil Inc.:
Basic
$
2.05
$
1.08
$
3.98
$
10.01
Diluted
$
2.03
$
1.06
$
3.94
$
9.86
Weighted average shares outstanding:
Basic
108.0
119.9
110.2
124.9
Diluted
109.3
121.7
111.5
126.9
JABIL INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions)
(Unaudited)
Nine months ended
May 31, 2025
May 31, 2024
Cash flows provided by operating activities:
Net income
$
439
$
1,250
Depreciation, amortization, and other, net
622
557
Gain from the divestiture of businesses
(45
)
(944
)
Change in operating assets and liabilities, exclusive of net assets acquired
36
318
Net cash provided by operating activities
1,052
1,181
Cash flows (used in) provided by investing activities:
Acquisition of property, plant and equipment
(299
)
(660
)
Proceeds and advances from sale of property, plant and equipment
60
115
Cash paid for business and intangible asset acquisitions, net of cash
(393
)
(90
)
Proceeds from the divestiture of businesses, net of cash
54
2,108
Other, net

(6
)
Net cash (used in) provided by investing activities
(578
)
1,467
Cash flows used in financing activities:
Borrowings under debt agreements
1,604
1,895
Payments toward debt agreements
(1,720
)
(1,987
)
Payments to acquire treasury stock
(975
)
(1,824
)
Dividends paid to stockholders
(28
)
(32
)
Net proceeds from exercise of stock options and issuance of common stock under employee stock purchase plan
33
31
Treasury stock minimum tax withholding related to vesting of restricted stock
(41
)
(68
)
Other, net
(38
)
(4
)
Net cash used in financing activities
(1,165
)
(1,989
)
Effect of exchange rate changes on cash and cash equivalents
13
(6
)
Net (decrease) increase in cash and cash equivalents
(678
)
653
Cash and cash equivalents at beginning of period
2,201
1,804
Cash and cash equivalents at end of period
$
1,523
$
2,457
JABIL INC. AND SUBSIDIARIES
SUPPLEMENTAL DATA
RECONCILIATION OF U.S. GAAP FINANCIAL RESULTS TO NON-GAAP MEASURES
(in millions, except for per share data)
(Unaudited)
Three months ended
Nine months ended
May 31, 2025
May 31, 2024
May 31, 2025
May 31, 2024
Operating income (U.S. GAAP)
$
403
$
261
$
845
$
1,695
Amortization of intangibles
17
12
45
27
Stock-based compensation expense and related charges
19
3
84
72
Restructuring, severance and related charges(1)
16
55
144
252
Net periodic benefit cost

2
1
7
Business interruption and impairment charges, net(2)
1
14
10
14
Gain from the divestiture of businesses(3)
(45
)

(45
)
(944
)
Acquisition and divestiture related charges(3)
9
3
17
64
Adjustments to operating income
17
89
256
(508
)
Core operating income (Non-GAAP)
$
420
$
350
$
1,101
$
1,187
Net income attributable to Jabil Inc. (U.S. GAAP)
$
222
$
129
$
439
$
1,250
Adjustments to operating income
17
89
256
(508
)
Loss on securities(4)
46

46

Net periodic benefit cost

(2
)
(1
)
(7
)
Adjustments for taxes
(6
)
14
(18
)
51
Core earnings (Non-GAAP)
$
279
$
230
$
722
$
786
Diluted earnings per share (U.S. GAAP)
$
2.03
$
1.06
$
3.94
$
9.86
Diluted core earnings per share (Non-GAAP)
$
2.55
$
1.89
$
6.48
$
6.20
Diluted weighted average shares outstanding (U.S. GAAP and Non-GAAP)
109.3
121.7
111.5
126.9
____________________
(1)
Charges recorded during the three months and nine months ended May 31, 2025 and May 31, 2024, primarily related to the 2025 Restructuring Plan and 2024 Restructuring Plan, respectively.
(2)
Charges recorded during the nine months ended May 31, 2025, relate primarily to costs associated with damage from Hurricanes Helene and Milton, which impacted our operations in St. Petersburg, Florida and Asheville and Hendersonville, North Carolina. Charges recorded during the three months and nine months ended May 31, 2024, related to costs associated with product quality liabilities.
(3)
We completed the divestiture of our Mobility Business and recorded a pre-tax gain of $944 million during the nine months ended May 31, 2024. Certain post-closing adjustments were realized in March 2025, which resulted in the recognition of a $54 million pre-tax gain during the three months ended May 31, 2025. We incurred transaction and disposal costs in connection with the sale of approximately $64 million during the nine months ended May 31, 2024.
(4)
Charges recorded during the three months and nine months ended May 31, 2025, relate to an impairment of an investment in Preferred Stock.
JABIL INC. AND SUBSIDIARIES
SUPPLEMENTAL DATA
ADJUSTED FREE CASH FLOW
(in millions)
(Unaudited)
Nine months ended
May 31, 2025
May 31, 2024
Net cash provided by operating activities (U.S. GAAP)
$
1,052
$
1,181
Acquisition of property, plant and equipment ("PP&E")(1)
(299
)
(660
)
Proceeds and advances from sale of PP&E(1)
60
115
Adjusted free cash flow (Non-GAAP)
$
813
$
636
____________________
(1)
Certain customers co-invest in PP&E with us. As we acquire PP&E, we recognize the cash payments in acquisition of PP&E. When our customers reimburse us and obtain control, we recognize the cash receipts in proceeds and advances from the sale of PP&E.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250617518463/en/
Contacts
Investor Contact Adam BerrySenior Vice President, Investor Relations and CommunicationsAdam_Berry@jabil.com
Media Contact Timur AydinSenior Director, Enterprise Marketing and Communicationspublicrelations@jabil.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds
Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds

Yahoo

time29 minutes ago

  • Yahoo

Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds

STATEN ISLAND, N.Y., June 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a warrant inducement agreement (the "Letter Agreement") with a certain holder ("Holder") of existing warrants to purchase up to an aggregate of 4,445,435 shares of common stock (the "Existing Warrants") having exercise prices ranging from $3.25 to $3.26 per share, issued by the Company in July 2022 and May 2023, wherein the Holder agreed to exercise the Existing Warrants at a reduced exercise price of $0.675 per share, resulting in gross proceeds of approximately $2.67 million, before deducting offering fees and other expenses payable by the Company. In consideration for the exercise of the Existing Warrants for cash, the investors received 6,223,609 G-1 warrants (the "G-1 Warrants") and 2,667,261 G-2 warrants (the "G-2 Warrants) to purchase up to an aggregate of 8,890,870 shares of common stock (the "New Warrants"). The G-1 Warrants are exercisable immediately at an exercise price of $0.425 per common share and will expire five years from the issuance date. The G-2 Warrants are exercisable upon shareholder approval at an exercise price of $0.425 per common share and will expire five years from the issuance date. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to effective resale registration statements on Form S-1 (File Nos. 333-267412 and 333-273015). The transaction is expected to close no later than June 20, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the exercise for working capital and general corporate purposes. The New Warrants are being issued in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Regulation D promulgated thereunder and, along with the shares of common stock underlying such New Warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the New Warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Ibezapolstat Ibezapolstat is the Company's lead antibiotic candidate advancing to international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS®) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome. In June 2018, ibezapolstat was designated by the U.S. Food and Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible to benefit from the incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI. About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillinresistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). To learn more about Acurx Pharmaceuticals and its product pipeline, please visit Forward-Looking Statements Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, the timing and completion of the offering; the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2024, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law. Investor Contact: Acurx Pharmaceuticals, Inc. David P. Luci, President & Chief Executive Officer Tel: 917-533-1469 Email: davidluci@ View original content: SOURCE Acurx Pharmaceuticals, Inc. Sign in to access your portfolio

On his first day with the Giants, Rafael Devers finds a whole new reality
On his first day with the Giants, Rafael Devers finds a whole new reality

New York Times

time29 minutes ago

  • New York Times

On his first day with the Giants, Rafael Devers finds a whole new reality

One meeting, that's all it took. One meeting with his new San Francisco Giants superiors, and suddenly Rafael Devers no longer was Rafael Diva. Funny how that works when bosses communicate their wishes, and do not simply assume a player with a $313.5 million contract should do whatever they want. People skills. They might be baseball's new market inefficiency. Advertisement The Boston Red Sox never shared their intentions with Devers when they were trying to sign free-agent third baseman Alex Bregman, prompting Devers to initially balk at becoming a DH and then outright refuse to move to first base. The Giants related to Devers that only four teams entered Tuesday with a worse OPS at first base, or something to that effect. And voila! There was Devers, all smiles at his introductory news conference, saying, 'I am here to play wherever they want me to play.' Including first base, where he took grounders before his Giants debut. 'I don't think it's going to be too difficult for him,' Giants manager Bob Melvin said. 'More than anything, the fact he hasn't played in the field this year, we have to take our time working him in. It's a new position. We'll take it day to day.' Devers is not above reproach for refusing to do the same for the Red Sox, no matter how much he believes they slighted him. But here's rooting for this trade to work out for Giants president of baseball operations Buster Posey, and not simply because he appears to have a better feel for players than Red Sox chief baseball officer Craig Breslow. Or even his predecessor, Farhan Zaidi, who made the same mistake with Brandon Crawford that Breslow did with Devers, failing to inform his incumbent shortstop that he was agreeing to terms with another, Carlos Correa.  This deal is a referendum on teams that define players more as 'dudes' – Posey's word – than 'assets.' A referendum on all the other fancy terms executives use, from flexibility to sustainability to efficiency, while hedging their bets and operating out of fear. A referendum on absorbing contracts that might not age well to do what every team should be trying to do – win. Devers' remaining $255 million or so over the next eight-plus years isn't as onerous as it might appear. Not when accounting for the approximately $32 million the Giants offloaded in the deal by including right-hander Jordan Hicks. And not when Vladimir Guerrero just signed a 14-year, $500 million extension that will begin next season when he is 27, one year younger than Devers is now. Guerrero's career OPS+ is 136. Devers' is 129. Advertisement Yet, the opinion of a number of rival executives, as related by The Athletic's Britt Ghiroli, is that the Red Sox all but pulled a fast one on the Giants. 'Freeing up $250 million AND getting some nice young talent in return is a great deal for them in a vacuum,' one exec said. 'In a few years I think this trade will be lauded,' another opined. Perhaps that is true. Perhaps Devers' questionable conditioning and lack of athleticism will cause him to decline faster than most. Perhaps two of the four players the Red Sox acquired, left-hander Kyle Harrison and 2024 first rounder James Tibbs III, will develop into a quality starting pitcher and productive outfielder, respectively. But once upon a time, before teams became obsessed with projections and modeling, the most effective way to evaluate a trade was by asking the question: Who got the best player in the deal? Without question, the best player in this deal is Devers, for this season and likely several beyond. And all those in the industry questioning Posey's bold move need to acknowledge that the Giants are operating in unique circumstances, not a vacuum. The Giants in recent years repeatedly were rejected by top sluggers, from Giancarlo Stanton to Bryce Harper, Aaron Judge to Shohei Ohtani. Citing medical concerns, they backed out of a deal on a player who was willing to come, Correa. Devers, lacking a no-trade clause (oops!), could not reject them. So paying a premium for him, if that's what it even was, made more sense for the Giants than it did for other clubs. Obviously, not all teams are willing or able to make the same type of commitments as the Giants, who within the last 10 months also retained third baseman Matt Chapman for $151 million and signed free-agent shortstop Willy Adames for $182 million. And let's not ignore reality. Posey, who became president of baseball operations last September, likely will learn the same hard lessons that scar many of his peers: Big deals often do not work out. Advertisement Yet, too often in this sport, teams in markets large and small hedge their bets, playing for tomorrow. Posey, who helped the Giants win three World Series as a player, is having none of it. In an interview earlier this month with the San Francisco Standard's Tim Kawakami, Posey all but signaled his approach to trading season, saying he 'loved' the Giants' 2011 acquisition of outfielder Carlos Beltrán, a rental, for right-hander Zack Wheeler, then a top 100 prospect. The move didn't work out. The Giants failed to make the playoffs that season. Wheeler, after overcoming a series of injuries, including Tommy John surgery, became one of the top pitchers in the game. But Posey, then the Giants' catcher, appreciated, 'the leader of our operation saying, 'Believe in you guys.'' The acquisition of Devers sends the same message, addressing the biggest need of a team that entered Tuesday third in the majors in ERA but only 14th in runs per game. Breslow, of course, believes in his team, too, as he made clear in his own news conference Monday. He indicated he would be active at the deadline, trying to replace some of the offense he lost with Devers. But of course, he never should have lost Devers in the first place. Breslow took responsibility for the breakdown in communication with his biggest star, saying, 'I absolutely need to have the humility to think back on the interactions and figure out what I could have done better.' But he also said the outcome might not have turned out differently, and portrayed Devers as a potentially negative influence on the team's young players. 'As we think about the identity, culture and environment that is created by great teams, there was something amiss here,' Breslow said. 'It was something we needed to act decisively to course-correct.' Well, the Red Sox's pattern of messy divorces with star players also is a threat to their identity, culture and environment, one that should give Roman Anthony and Co. pause when the team comes calling with extensions. Advertisement Breslow, like Posey, is a former player, a pitcher who spent 12 seasons in the majors from 2005 to '17. But while Posey draws praise from Giants players for his presence and leadership, Breslow is perceived by many inside and outside the Red Sox organization as remote, almost robotic. 'Alignment' – that was the fancy word Breslow and Red Sox CEO Sam Kennedy kept using Monday to describe what was missing with Devers. Posey spoke in much plainer terms Tuesday when describing Devers as a 'dude' and saying the qualities of such a player 'are not something you can quantify.' Introductory news conferences are always cause for celebration, and carry only so much weight. But the difference in Devers, who often shunned the media during his final months in Boston, was unmistakable. He laughed. He joked. He referenced Giants legend Barry Bonds sitting in the front row and cracked, 'Just looking at him, my game has improved a lot.' Funny how quickly the Giants turned Rafael Diva into Rafael Devers again. (Top photo of Rafael Devers: Thearon W. Henderson/Getty Images)

US Fed set to hold rates steady as it guards against inflation
US Fed set to hold rates steady as it guards against inflation

Yahoo

time34 minutes ago

  • Yahoo

US Fed set to hold rates steady as it guards against inflation

The US central bank is expected to hold interest rates steady Wednesday after its key policy meeting, as officials gauge the impact of tariffs on inflation -- and despite President Donald Trump's calls for rate cuts. The Federal Reserve has kept the benchmark lending rate unchanged this year at a range between 4.25 percent and 4.50 percent, and analysts expect policymakers will remain on the sidelines until price increases cool sustainably. While Trump has imposed a 10 percent tariff on most US trading partners and steeper levies on imports of steel, aluminum and autos in recent months, these have not triggered a price surge so far. This is partly because Trump has backed off or postponed some of his most punishing salvos, while businesses in turn have relied on existing inventory to avoid hiking consumer costs immediately. In May, the consumer price index edged up to 2.4 percent on-year from 2.3 percent in April, underscoring the limited effect of levies for now. But economists expect it will take several months for tariffs to flow into consumer prices, and the Fed is proceeding cautiously with interest rate adjustments. "The Fed would no doubt be cutting again by now if not for the uncertainty regarding tariffs and a recent escalation of tensions in the Middle East," said KPMG senior economist Benjamin Shoesmith. The prospect of higher inflation will probably keep the central bank in "wait-and-see mode for much of this year," he added in a note. Officials will want to see "if those factors trigger more than a transitory increase in prices," he said. Beyond inflation data, policymakers are also trying to keep expectations "anchored," a state in which consumers expect price increases to remain low and steady. If there are widespread expectations of price hikes, inflation could rise as businesses increase customer costs and workers seek higher wages. On Wednesday, the Fed is also due to release its latest economic projections on growth, unemployment and inflation. Analysts will monitor if the Fed still expects to make two more rate cuts this year as well. - 'Saber-rattling' - For his part, Trump has repeatedly urged the independent central bank to slash rates, calling Fed Chair Jerome Powell "too late" in doing so and "a fool" for holding off further cuts at the bank's May meeting. Trump has pointed to benign US inflation in arguing for interest rate cuts. More recently, he also cast such a move as a way for the country to "pay much less interest on debt coming due," overlooking the fact that lower interest rates usually raise consumer prices. Powell however has maintained that the Fed's rate-setting committee would make its decisions based solely on objective and non-political analysis, the Fed previously said. The Fed chair has also defended US central bank independence over rates in his recent meeting with Trump. Despite Trump's pressure, Allianz Trade North America senior economist Dan North expects Powell will not be too shaken by "saber-rattling." "Consumers are still spending, labor markets still creating jobs, although it is in fact slowing a little bit," North told AFP. "Certainly, the health of the economy doesn't beg for the Fed to cut rates," he added. "So we think they're on hold till the end of the year." myl-bys/dw Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store